Filana Therapeutics (MEX:FLNA) Other Current Liabilities: MXN5.79 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:FLNA Filana Therapeutics Inc MEX:FLNA
32 GF Score
Price MXN23.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Other Current Liabilities?

Filana Therapeutics MEX:FLNA 32 Other Current Liabilities is MXN5.79 Mil as of Mar. 2026. GuruFocus rates MEX:FLNA with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Filana Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was MXN5.79 Mil.

Filana Therapeutics's quarterly other current liabilities increased from Sep. 2025 (MXN10.79 Mil) to Dec. 2025 (MXN32.82 Mil) but then declined from Dec. 2025 (MXN32.82 Mil) to Mar. 2026 (MXN5.79 Mil).

Filana Therapeutics's annual other current liabilities increased from Dec. 2023 (MXN9.93 Mil) to Dec. 2024 (MXN34.54 Mil) but then declined from Dec. 2024 (MXN34.54 Mil) to Dec. 2025 (MXN32.82 Mil).

Filana Therapeutics Other Current Liabilities Related Terms

Filana Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics Other Current Liabilities Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.45 12.91 9.93 34.54 32.82

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.80 13.60 10.79 32.82 5.79
MEX:FLNA
32GF Score
Filana Therapeutics Inc MEX:FLNA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN5.79 Mil mean?
Filana Therapeutics (MEX:FLNA) has a Other Current Liabilities of MXN5.79 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Filana Therapeutics.
Is Filana Therapeutics' Other Current Liabilities too high?
Filana Therapeutics' current Other Current Liabilities is MXN5.79 Mil. Overall, Filana Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' Other Current Liabilities compare to BOLD and INKT?
Filana Therapeutics' Other Current Liabilities of MXN5.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Filana Therapeutics. Filana Therapeutics's current Other Current Liabilities is MXN5.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (MEX:FLNA) has a current Other Current Liabilities of MXN5.79 Mil. The current Other Current Liabilities is MXN5.79 Mil. Filana Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Filana Therapeutics (MEX:FLNA), the current Other Current Liabilities is MXN5.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
32GF Score

Get the complete analysis for MEX:FLNA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN23.00
Price